Recent Updates
Recently added Catalysts

PIK3CA-related Overgrowth Spectrum: one US-listed biotech with a clinical-stage programme

Rare Genetic & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$4.2Buniverse median $1.20B
Allocated capital$4.2B$4.2B competing
Phase 3 or filed01 mid, 0 early
Pure plays1this indication only
Capital rank45/299crowding rank 106

PIK3CA-related Overgrowth Spectrum is uncontested. Relay Therapeutics (RLAY) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with RLY-2608 in phase 2.

There is no public comparable to price it against, and RLAY runs clinical programmes in this indication and nothing else, so its $4.2B market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$4.2B of allocated capital sits in PIK3CA-related Overgrowth Spectrum, ranking it 45th of 299 indications by the money committed to it.

Companies developing drugs for PIK3CA-related Overgrowth Spectrum 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
RLAYRelay TherapeuticsRLY-2608Phase 21$4.2BYes1 30 Jun 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why PIK3CA-related Overgrowth Spectrum counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. PIK3CA-related Overgrowth Spectrum has one competitor and a median of $4.2B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Sickle Cell Disease6 companies · $4.8B · median $2.5BGold rushFacioscapulohumeral Muscular Dystrophy2 companies · $3.5B · median $3.5BConcentrated betCystic Fibrosis4 companies · $3.1B · median $605MOrphan cornerPhenylketonuria4 companies · $5.6B · median $4.0BConcentrated betDystrophic Epidermolysis Bullosa1 company · $2.2B · median $11.0BUncontestedAcquired Angioedema1 company · $1.2B · median $2.3BUncontestedMECP2 Duplication Syndrome1 company · $1.1B · median $9.7BUncontestedVon Willebrand Disease1 company · $1.0B · median $2.1BUncontested

PIK3CA-related Overgrowth Spectrum pipeline questions

Which biotech companies are developing drugs for PIK3CA-related Overgrowth Spectrum?

Relay Therapeutics (RLAY, RLY-2608, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in PIK3CA-related Overgrowth Spectrum.

How advanced is the PIK3CA-related Overgrowth Spectrum pipeline?

Of the 1 clinical-stage programme in PIK3CA-related Overgrowth Spectrum, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for PIK3CA-related Overgrowth Spectrum?

No. RLAY is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in PIK3CA-related Overgrowth Spectrum, which is why the indication is classified as uncontested.

When is the next PIK3CA-related Overgrowth Spectrum catalyst?

The next dated catalyst in PIK3CA-related Overgrowth Spectrum is RLAY on 30 Jun 2027. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map